At a glance
ClinicalIndex Comparison RecordPhase 2Completed· 5 enrolled
Drug / intervention
GBT440drug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
An Open Label Single Arm Extension Study to Further Evaluate the Safety, Tolerability and Treatment Response of GBT440 in Patients With Sickle Cell Disease Who Participated in the Phase 1 Study GBT440-001
In Brief
A Phase 2 clinical trial evaluating GBT440 for Sickle Cell Disease. Completed, enrolled 5 participants across 1 site.
Detailed Summary
This is an open label, single arm study which enrolled 5 subjects with SCD who previously participated in the GBT440-001 study (NCT02285088).
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsSickle Cell Disease
CountriesUnited Kingdom
Collaborators--
Timeline
Phase 2CompletedFinished
2017201820192020202120222023202420252026
Enrollment StartAug 2016
First PostedFeb 2017
Primary CompletionJun 2017
Study CompletionAug 2017
TodayJul 2026
First PostedFeb 3, 2017
Enrollment StartAug 1, 2016
Primary CompletionJun 1, 2017
Study CompletionAug 1, 2017
TodayJul 2, 2026
Enrollment to primary: 10 monthsPosted 9.4 years ago
Interventions
GBT440drug
Oral drug